Payment overview · 2025
General Payments
$48.69
2 reported records · 1 companies
Healthcare provider profile · identity verified
David A Ward, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ENID, OK · NPI 1053409052
Verified facts
What the public records show
CMS Open Payments records show David A Ward, ARNP received $48.69 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.69 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.69 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.69 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 595 | 157 |
| Gabapentin | Gabapentin | 381 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 88 |
| Omeprazole | Omeprazole | 275 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 57 |
| Losartan Potassium | Losartan Potassium | 265 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 62 |
| Lisinopril | Lisinopril | 200 | 55 |
| Meloxicam | Meloxicam | 183 | 56 |
| Trazodone Hcl | Trazodone Hcl | 179 | 41 |
| Alprazolam | Alprazolam | 178 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 46 |
| Potassium Chloride | Potassium Chloride | 146 | 42 |
| Mounjaro | Tirzepatide | 145 | 24 |
| Jardiance | Empagliflozin | 143 | 34 |
| Simvastatin | Simvastatin | 143 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 143 | 39 |
| Furosemide | Furosemide | 141 | 49 |
| Tramadol Hcl | Tramadol Hcl | 138 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 40 |
| Sertraline Hcl | Sertraline Hcl | 132 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 34 |
| Ozempic | Semaglutide | 116 | 22 |
| Montelukast Sodium | Montelukast Sodium | 111 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 24 |
| Famotidine | Famotidine | 95 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 30 |
| Metformin Hcl | Metformin Hcl | 90 | 27 |
| Carvedilol | Carvedilol | 85 | 22 |
| Allopurinol | Allopurinol | 82 | 23 |
| Celecoxib | Celecoxib | 82 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 21 |
| Eliquis | Apixaban | 78 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 18 |
| Cephalexin | Cephalexin | 74 | 53 |
| Prednisone | Prednisone | 74 | 54 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 21 |
| Farxiga | Dapagliflozin Propanediol | 65 | 18 |
| Glipizide Er | Glipizide | 65 | 20 |
| Spironolactone | Spironolactone | 61 | 18 |
| Januvia | Sitagliptin Phosphate | 60 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 11 |
| Metformin Hcl Er | Metformin Hcl | 60 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 20 |
| Naproxen | Naproxen | 58 | 16 |
| Pregabalin | Pregabalin | 58 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Trulicity | Dulaglutide | 57 | 11 |
| Alendronate Sodium | Alendronate Sodium | 55 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 14 |
| Ezetimibe | Ezetimibe | 51 | 17 |
| Atenolol | Atenolol | 47 | 11 |
| Methylprednisolone | Methylprednisolone | 47 | 41 |
| Cefdinir | Cefdinir | 46 | 41 |
| Temazepam | Temazepam | 46 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 44 | 13 |
| Azithromycin | Azithromycin | 41 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 12 |
| Estradiol | Estradiol | 37 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Clozapine | Clozapine | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 14 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 15 |
| Topiramate | Topiramate | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 12 |
| Meclizine Hcl | Meclizine Hcl | 20 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Valsartan | Valsartan | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.69 · 2 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error